

**Amendments To The Claims**

1-28. (Canceled)

29. (Amended) An isolated unconjugated monoclonal antibody that specifically binds phosphatidyl serine and that induces complement dependent cell-mediated cytotoxicity against a human tumor cell that expresses phosphatidyl serine;

wherein the light chain V region of said antibody is also present in the light chain of ~~an antibody that recognizes e-aminocaproic acid~~ the 2E7 antibody, and

wherein the heavy chain V region of said antibody is also present in the heavy chain of ~~an antibody that recognizes p-azaphenylarsenate~~ the 2E7 antibody.

30. (Canceled) The monoclonal antibody of claim 29 which is a primate antibody.

31. (Canceled) The monoclonal antibody of claim 29 which is a human antibody.

32. (Previously presented) The monoclonal antibody of claim 29 which is a chimeric antibody.

33. (Previously presented) The monoclonal antibody of claim 29 which is a humanized antibody.

34. (Previously presented) A pharmaceutical composition containing a monoclonal antibody according to claim 29.

35. (Canceled) The pharmaceutical composition of claim 34 wherein the monoclonal antibody is a primate antibody.

36. (Canceled) The pharmaceutical composition of claim 34 wherein the monoclonal antibody is a human antibody.

37. (Previously presented) The pharmaceutical composition of claim 34 wherein the monoclonal antibody is a chimeric antibody.

38. (Previously presented) The pharmaceutical composition of claim 34 wherein the monoclonal antibody is a humanized antibody.